- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2021–2026 · research · R01
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · grant · KCRP
Harnessing Epigenomics to Detect and Target Sarcomatoid Differentiation in Renal Cell Carcinoma
Sylvan Baca · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2024 · research · R01
Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials
Lorenzo Trippa · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs
Sarah E Johnstone · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma
Megan Leigh Insco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R21
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · grant · DP2
How the 3D architecture of the brain shapes cancer cell fate decisions
Mariella Gruber Filbin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · research · R01
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · grant · PRCRP
Determining the Molecular Basis and Therapeutic Potential of Hyperactive Stem Cell Programs in Colorectal Cancer
Nilay Sethi · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R01
Defining epigenetic mechanisms in NPM1c mutant leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
Stephanie Dougan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · fellowship · F32
Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy Response
Nathaniel Mabe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · research · R01
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs
Sarah E Johnstone · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma
Megan Leigh Insco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · fellowship · F32
Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy Response
Nathaniel Mabe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency
Pietro Genovese · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · fellowship · F32
Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma
Leslie Lupien · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K08
Insights from somatic genomics lead to novel therapeutic targets in inherited bone marrow failure syndromes: Shwachman-Diamond Syndrome as a model.
Alyssa Kennedy · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Can a subset of patients with HER2+ metastatic breast cancer be cured?
Heather Anne Parsons · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R21
Integrative molecular dissection of acquired resistance to PD1/PD-L1 blockade in localized and metastatic urothelial carcinoma
David J. Kwiatkowski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Defining epigenetic mechanisms in NPM1c mutant leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
Christopher James Gibson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2022 · grant · KCRP
Uncovering a Role for TFE3 Fusion Partners in Driving Translocation Renal Cell Carcinoma
Shatha Abuhammad · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2023 · career development · K99
Targeting mechanical regulation of monocyte fate in head and neck cancer.
Kyle Holmberg Vining · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · research · R01
DMS/NIGMS 1: Statistical modeling and estimation of cellular population dynamics
Thomas Mcdonald · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2027 · career development · K00
Elucidating the Mechanisms of Translational Approaches to Enhance Recovery of Aged Muscle
Jonathan Joseph Petrocelli · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia
Shan Lin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Defining epigenetic mechanisms in NPM1c mutant leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · grant · OCRP
Novel Synergistic ATR Inhibitor Combinations for Ovarian Cancer Therapy
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R01
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · grant · KCRP
Pre-IND Studies of First-Generation Dual-Targeted, Fine-Tuned, Immune-Restoring (DFIR) CAR-T Cell Therapy to Achieve Cures of Advanced Clear Cell Renal Cell Carcinoma
David Barbie · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R01
Statistical methods for cancer mutational signatures
Giovanni Luigi Parmigiani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Can a subset of patients with HER2+ metastatic breast cancer be cured?
Heather Anne Parsons · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · research · R01
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2022 · career development · K99
Targeting mechanical regulation of monocyte fate in head and neck cancer.
Kyle Holmberg Vining · Dana-Farber Cancer Institute · funded by National Institutes of Health
